Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease

Am J Gastroenterol. 2024 Nov 14. doi: 10.14309/ajg.0000000000003208. Online ahead of print.

Abstract

Introduction: The safety and effectiveness of glucagon-like peptide receptor agonists (GLP1-RA) in patients with inflammatory bowel disease (IBD) are poorly understood.

Methods: Patients with IBD treated with GLP1-RA were retrospectively identified for outcomes of adverse events, weight change, and clinical, endoscopic, and biomarker response.

Results: Among a total of 120 patients with IBD, gastrointestinal side effects being the most common (11.5%). Semaglutide showed the most significant weight reduction. C-reactive protein levels decreased after one year (P = 0.005). No differences were observed in IBD-related hospitalizations or endoscopic scores.

Discussion: GLP1-RA therapy appears safe and effective, with an associated C-reactive protein reduction, in patients with IBD.